7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013)


A daily dose of 400mg efavirenz (EFV) is non-inferior to the standard 600mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial WELBB01


Time: 16:30
Speaker: Rebekah Puls



This text willreplaced

You can download the video file here



For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.